ETNB RA Capital Healthcare Fund LP buys $50.0M worth of shares
Mar 27, 2025, 10:36 AM
-13.47%
What does ETNB do
89bio, a San Francisco-based biopharmaceutical company, focuses on therapies for liver and cardio-metabolic diseases, with its lead candidate, pegozafermin, targeting nonalcoholic steatohepatitis and severe hypertriglyceridemia. The company went public on November 11, 2019, and employs 70 people.
RA Capital Healthcare Fund LP bought 5,714,285 shares of ETNB on 30 January at $8.75 per share, worth a total of $50.0M. They now own 19,554,319 ETNB shares, or a 41% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.